Analysis of 34 candidate genes in bupropion and placebo remission

International Journal of Neuropsychopharmacology

Volumn 16, Issue 4, 2013, Pages 771-781

  Tiwari, Arun K ^a   Zai, Clement C ^a   Sajeev, Gautam ^a   Arenovich, Tamara ^a   Müller, Daniel J ^a   Kennedy, James L ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Association; bupropion; dopamine; placebo; response; serotonin

Indexed keywords

AMFEBUTAMONE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; DOPAMINE TRANSPORTER; GLUCOCORTICOID RECEPTOR; PLACEBO; SEROTONIN 2 RECEPTOR; VESICULAR MONOAMINE TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER 1; VESICULAR MONOAMINE TRANSPORTER 2;

ADULT; ARTICLE; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HAMILTON SCALE; HAPLOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY (TOPIC); PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT2A; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875691194     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000843     Document Type: Article

References (49)

1. Alex KD, Pehek EA (2007). Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacology and Therapeutics 113, 296-320.
2. Annerbrink K, Jonsson EG, Olsson M, Nilsson S, et al. (2010). Associations between the angiotensin-converting enzyme insertion/deletion polymorphism and monoamine metabolite concentrations in cerebrospinal fluid. Psychiatry Research 179, 231-234.
3. Arias HR, Santamaria A, Ali SF (2009). Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. International Review of Neurobiology 88, 223-255.
4. Baghai TC, Binder EB, Schule C, Salyakina D, et al. (2006). Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Molecular Psychiatry 11, 1003-1015.
5. Baghai TC, Schule C, Zill P, Deiml T, et al. (2004). The angiotensin I converting enzyme insertion/deletion polymorphism influences therapeutic outcome in major depressed women, but not in men. Neuroscience Letters 363, 38-42.
6. Barrett JC, Fry B, Maller J, Daly MJ (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265.
7. Benedetti F, Carlino E, Pollo A (2011). How placebos change the patient's brain. Neuropsychopharmacology 36, 339-354.
8. Binder EB, Owens MJ, Liu W, Deveau TC, et al. (2010). Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Archives of General Psychiatry, 67, 369-379.
9. Binder EB, Salyakina D, Lichtner P, Wochnik GM, et al. (2004). Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nature Genetics 36, 1319-1325.
10. Bondy B, Baghai TC, Zill P, Schule C, et al. (2005). Genetic variants in the angiotensin I-converting-enzyme (ACE) and angiotensin II receptor (AT1) gene and clinical outcome in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29, 1094-1099.
11. Buckholtz JW, Meyer-Lindenberg A (2008). MAOA and the neurogenetic architecture of human aggression. Trends in Neurosciences 31, 120-129.
12. Clayton AH, Croft HA, Horrigan JP, Wightman DS, et al. (2006). Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. Journal of Clinical Psychiatry 67, 736-746.
13. de la Fuente-Fernandez R (2009). The placebo-reward hypothesis: dopamine and the placebo effect. Parkinsonism and Related Disorders 15 (Suppl. 3), S72-S74.
14. Drago A, de Ronchi D, Serretti A (2009). Pharmacogenetics of antidepressant response: an update. Human Genomics 3, 257-274.
15. Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT (2006). Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Reviews 12, 178-207.
16. Franchini L, Serretti A, Gasperini M, Smeraldi E (1998). Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. Journal of Psychiatric Research 32, 255-259.
17. Furmark T, Appel L, Henningsson S, Ahs F, et al. (2008). A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. Journal of Neuroscience 28, 13066-13074.
18. Garriock HA, Kraft JB, Shyn SI, Peters EJ, et al. (2010a). A genomewide association study of citalopram response in major depressive disorder. Biological Psychiatry 67, 133-138.
19. Garriock HA, Tanowitz M, Kraft JB, Dang VC, et al. (2010b). Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. American Journal of Psychiatry 167, 565-573.
20. Gauderman WJ, Morrison JM (2006). QUANTO 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies. (http://hydra.usc.edu/gxe) Accessed 17 September 2010.
21. Gill P (2001). An assessment of the utility of single nucleotide polymorphisms (SNPs) for forensic purposes. International Journal of Legal Medicine 114, 204-210.
22. Heck A, Lieb R, Ellgas A, Pfister H, et al. (2009). Polymorphisms in the angiotensin-converting enzyme gene region predict coping styles in healthy adults and depressed patients. American Journal of Medical Genetics 150B, 104-114.
23. Horstmann S, Binder EB (2009). Pharmacogenomics of antidepressant drugs. Pharmacology and Therapeutics 124, 57-73.
24. Hu XZ, Rush AJ, Charney D, Wilson AF, et al. (2007). Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Archives of General Psychiatry 64, 783-792.
25. Jefferson JW, Rush AJ, Nelson JC, VanMeter SA, et al. (2006). Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 67, 865-873.
26. Kato M, Serretti A (2010). Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular Psychiatry 15, 473-500.
27. Kessler RC, Berglund P, Demler O, Jin R, et al. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 62, 593-602.
28. Kitamura Y, Fujitani Y, Kitagawa K, Miyazaki T, et al. (2008). Effects of imipramine and bupropion on the duration of immobility of ACTH-treated rats in the forced swim test: involvement of the expression of 5-HT2A receptor mRNA. Biological and Pharmaceutical Bulletin 31, 246-249.
29. Koren-Michowitz M, Shimoni A, Vivante A, Trakhtenbrot L, et al. (2008). A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD). Leukemia Research 32, 421-427.
30. Kranz GS, Kasper S, Lanzenberger R (2010). Reward and the serotonergic system. Neuroscience 166, 1023-1035.
31. Leuchter AF, Cook IA, Witte EA, Morgan M, et al. (2002). Changes in brain function of depressed subjects during treatment with placebo. American Journal of Psychiatry 159, 122-129.
32. Leuchter AF, McCracken JT, Hunter AM, Cook IA, et al. (2009). Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. Journal of Clinical Psychopharmacology 29, 372-377.
33. Li J, Ji L (2005). Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 95, 221-227.
34. McMahon FJ, Buervenich S, Charney D, Lipsky R, et al. (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. American Journal of Human Genetics 78, 804-814.
35. Mayberg HS, Silva JA, Brannan SK, Tekell JL, et al. (2002). The functional neuroanatomy of the placebo effect. American Journal of Psychiatry 159, 728-737.
36. Nyholt DR (2004). A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. American Journal of Human Genetics 74, 765-769.
37. Paclt I, Koudelova J, Pacltova D, Kopeckova M (2009). Dopamine beta hydroxylase (DBH) plasma activity in childhood mental disorders. Neuroendocrinology Letters 30, 604-609.
38. Pritchard JK, Stephens M, Donnelly P (2000). Inference of population structure using multilocus genotype data. Genetics 155, 945-959.
39. Purcell S, Neale B, Todd-Brown K, Thomas L, et al. (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. American Journal of Human Genetics 81, 559-575.
40. Rau KS, Birdsall E, Hanson JE, Johnson-Davis KL, et al. (2005). Bupropion increases striatal vesicular monoamine transport. Neuropharmacology 49, 820-830.
41. Rief W, Nestoriuc Y, Weiss S, Welzel E, et al. (2009). Meta-analysis of the placebo response in antidepressant trials. Journal of Affective Disorders 118, 1-8.
42. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, et al. (2003). The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry 54, 573-583.
43. Serretti A, Kato M, De Ronchi D, Kinoshita T (2007). Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Molecular Psychiatry 12, 247-257.
44. Thase ME, Clayton AH, Haight BR, Thompson AH, et al. (2006). A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. Journal of Clinical Psychopharmacology 26, 482-488.
45. Thase ME, Haight BR, Richard N, Rockett CB, et al. (2005). Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. Journal of Clinical Psychiatry 66, 974-981.
46. Uher R, Huezo-Diaz P, Perroud N, Smith R, et al. (2009). Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics Journal 9, 225-233.
47. Uher R, Perroud N, Ng MY, Hauser J, et al. (2010). Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. American Journal of Psychiatry 167, 555-564.
48. Walsh BT, Seidman SN, Sysko R, Gould M (2002). Placebo response in studies of major depression: variable, substantial, and growing. Journal of the American Medical Association 287, 1840-1847.
49. Wray NR, James MR, Gordon SD, Dumenil T, et al. (2009). Accurate, large-scale genotyping of 5HTTLPR and flanking single nucleotide polymorphisms in an association study of depression, anxiety, and personality measures. Biological Psychiatry 66, 468-476.